Sifalimumab

Sifalimumab is an experimental drug that was developed by MedImmune, a subsidiary of AstraZeneca. It is a human monoclonal antibody that was designed for the treatment of systemic lupus erythematosus (SLE).

Mechanism of Action

Sifalimumab works by targeting and neutralizing interferon alpha, a protein that plays a key role in the inflammatory response in SLE.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of sifalimumab in patients with SLE. In a Phase IIb study, sifalimumab showed a reduction in disease activity in patients with moderate to severe SLE.

Development Status

As of 2016, AstraZeneca has discontinued the development of sifalimumab for SLE due to the results of a Phase IIb study.

See Also

• Monoclonal antibodies
• Systemic lupus erythematosus
• Interferon alpha

References

Sifalimumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski